Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer.

MedStar author(s):
Citation: Breast Cancer Research & Treatment. 172(1):221-230, 2018 Nov.PMID: 30022328Institution: MedStar Franklin Square Medical CenterForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Brain Neoplasms/me [Metabolism] | *Brain Neoplasms/rt [Radiotherapy] | *Breast Neoplasms/me [Metabolism] | *Breast Neoplasms/rt [Radiotherapy] | Adult | Aged | Aged, 80 and over | Brain Neoplasms/co [Complications] | Brain Neoplasms/sc [Secondary] | Breast Neoplasms/co [Complications] | Breast Neoplasms/pa [Pathology] | Diabetes Mellitus/me [Metabolism] | Diabetes Mellitus/pa [Pathology] | Diabetes Mellitus/su [Surgery] | Female | Humans | Middle Aged | Obesity/co [Complications] | Obesity/me [Metabolism] | Obesity/pa [Pathology] | Obesity/su [Surgery] | Prognosis | Radiosurgery/mt [Methods] | Treatment OutcomeYear: 2018ISSN:
  • 0167-6806
Name of journal: Breast cancer research and treatmentAbstract: CONCLUSIONS: Elevated BMI or diabetes may negatively impact both overall survival and local control in patients with brain metastases from breast cancer, highlighting the importance of the translational development of therapeutic metabolic interventions. Given its prognostic significance, BMI should be used as a stratification in future clinical trial design in this patient population.METHODS: We retrospectively identified 84 consecutive patients with brain metastases from breast cancer treated with intracranial radiation therapy. Radiation was delivered as whole-brain radiation to a median dose of 3000 cGy or stereotactic radiosurgery to a median dose of 2100 cGy. Kaplan Meier curves were generated for overall survival (OS) data and Mantel-Cox regression was performed to detect differences in groups.PURPOSE: Metabolic dysregulation has been implicated as a molecular driver of breast cancer in preclinical studies, especially with respect to metastases. We hypothesized that abnormalities in patient metabolism, such as obesity and diabetes, may drive outcomes in breast cancer patients with brain metastases.RESULTS: At analysis, 81 survival events had occurred and the median OS for the entire cohort was 21.7 months. Despite similar modified graded prognostic assessments, resection rates, and receptor status, BMI>=25 kg/m<sup>2</sup> (n=45) was associated with decreased median OS (13.7 vs. 30.6 months; p<0.001) and median intracranial progression-free survival (PFS) (7.4 vs. 10.9 months; p=0.04) compared to patients with BMI<25 kg/m<sup>2</sup> (n=39). Similar trends were observed among all three types of breast cancer. Patients with diabetes (n=17) had decreased median OS (11.8 vs. 26.2 months; p<0.001) and median intracranial PFS (4.5 vs. 10.3 months; p=0.001) compared to non-diabetics (n=67). On multivariate analysis, both BMI>=25 kg/m<sup>2</sup> [HR 2.35 (1.39-3.98); p=0.002] and diabetes [HR 2.77 (1.454-5.274); p=0.002] were associated with increased mortality.All authors: Andrews DW, Anne' PR, Dicker AP, Ko K, McCall NS, Mehta M, Nowak-Choi K, Rese A, Shi W, Simone BA, Simone NL, Venkataraman C, Zhan TFiscal year: FY2019Digital Object Identifier: Date added to catalog: 2018-07-30
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 30022328 Available 30022328

CONCLUSIONS: Elevated BMI or diabetes may negatively impact both overall survival and local control in patients with brain metastases from breast cancer, highlighting the importance of the translational development of therapeutic metabolic interventions. Given its prognostic significance, BMI should be used as a stratification in future clinical trial design in this patient population.

METHODS: We retrospectively identified 84 consecutive patients with brain metastases from breast cancer treated with intracranial radiation therapy. Radiation was delivered as whole-brain radiation to a median dose of 3000 cGy or stereotactic radiosurgery to a median dose of 2100 cGy. Kaplan Meier curves were generated for overall survival (OS) data and Mantel-Cox regression was performed to detect differences in groups.

PURPOSE: Metabolic dysregulation has been implicated as a molecular driver of breast cancer in preclinical studies, especially with respect to metastases. We hypothesized that abnormalities in patient metabolism, such as obesity and diabetes, may drive outcomes in breast cancer patients with brain metastases.

RESULTS: At analysis, 81 survival events had occurred and the median OS for the entire cohort was 21.7 months. Despite similar modified graded prognostic assessments, resection rates, and receptor status, BMI>=25 kg/m<sup>2</sup> (n=45) was associated with decreased median OS (13.7 vs. 30.6 months; p<0.001) and median intracranial progression-free survival (PFS) (7.4 vs. 10.9 months; p=0.04) compared to patients with BMI<25 kg/m<sup>2</sup> (n=39). Similar trends were observed among all three types of breast cancer. Patients with diabetes (n=17) had decreased median OS (11.8 vs. 26.2 months; p<0.001) and median intracranial PFS (4.5 vs. 10.3 months; p=0.001) compared to non-diabetics (n=67). On multivariate analysis, both BMI>=25 kg/m<sup>2</sup> [HR 2.35 (1.39-3.98); p=0.002] and diabetes [HR 2.77 (1.454-5.274); p=0.002] were associated with increased mortality.

English

Powered by Koha